TTK promotes HER2 + breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the Akt/mTOR axis
Which implies that TTK is an oncogene in HER2 + BRCA and is a valuable research target.
Authors
- Yu Ren (ORCID: https://orcid.org/0000-0003-2928-138X)
- Shaolin Zhang (ORCID: https://orcid.org/0000-0002-2259-7704)
- Yuwei Deng (ORCID: https://orcid.org/0000-0002-1480-6262)
- Qian Zhang (ORCID: https://orcid.org/0000-0002-0450-261X)
- Shu Liu (ORCID: https://orcid.org/0000-0003-2251-3934)
- Fulin Zhou (ORCID: https://orcid.org/0000-0002-5489-3356)
- Hua Ding (ORCID: https://orcid.org/0000-0001-5897-0534)
Institutions
- Guiyang Medical University (CN)
- Tongren Hospital (CN)
- People's Hospital of Kaizhou District (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Guiyang University (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1007/s00432-024-06021-9
- Citations
- 1
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- National Natural Science Foundation of China
- Guizhou Medical University